Optimal scheduling of radiotherapy and angiogenic inhibitors

DOI10.1016/S0092-8240(03)00006-5zbMATH Open1334.92196OpenAlexW2163741151WikidataQ73399851 ScholiaQ73399851MaRDI QIDQ253387FDOQ253387

Authors: Ayla Ergun, Kevin Camphausen, Lawrence M. Wein 

Publication date: 8 March 2016

Published in: Bulletin of Mathematical Biology (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1016/s0092-8240(03)00006-5

Recommendations

• Optimal combined radio- and anti-angiogenic cancer therapy
• On optimal delivery of combination therapy for tumors
• Optimizing the delivery of combination therapy for tumors: A mathematical model
• Optimal solutions for a model of tumor anti-angiogenesis with a penalty on the cost of treatment
• Scheduling of angiogenic inhibitors for Gompertzian and logistic tumor growth models

zbMATH Keywords

antiangiogenic monotherapyoptimal schedulingradiotherapyvascularized tumor

Mathematics Subject Classification ID

Medical applications (general) (92C50) Applications of optimal control and differential games (49N90)

Cited In (37)

• Dynamical properties of a minimally parameterized mathematical model for metronomic chemotherapy
• Qualitative analysis of tumor growth model under antiangiogenic therapy -- choosing the effective operating point and design parameters for controller design
• Optimal combined radio- and anti-angiogenic cancer therapy
• Optimization of antitumor radiotherapy fractionation via mathematical modeling with account of 4 R's of radiobiology
• Angiogenesis inhibition and tumor-immune interactions with chemotherapy by a control set-valued method
• Optimal response to chemotherapy for a mathematical model of tumor-immune dynamics
• Multi-input optimal control problems for combined tumor anti-angiogenic and radiotherapy treatments
• Optimizing chemoradiotherapy to target metastatic disease and tumor growth
• Optimisation of cancer drug treatments using cell population dynamics
• On optimal delivery of combination therapy for tumors
• Numerical solution for a problem arising in angiogenic signalling
• Optimal control for selected cancer chemotherapy ODE models: a view on the potential of optimal schedules and choice of objective function
• Optimizing the delivery of combination therapy for tumors: A mathematical model
• Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers
• Tumour eradication by antiangiogenic therapy: analysis and extensions of the model by Hahnfeldt et al. (1999)
• On probabilistic certification of combined cancer therapies using strongly uncertain models
• Analysis of anticancer efficiency of combined fractionated radiotherapy and antiangiogenic therapy via mathematical modelling
• Optimal control of a mathematical model for cancer chemotherapy under tumor heterogeneity
• An optimal control approach for the treatment of solid tumors with angiogenesis inhibitors
• Local controllability and optimal control for a model of combined anticancer therapy with control delays
• On an extension of a mathematical model for tumor anti-angiogenesis
• Analysis of the Hopf bifurcation for the family of angiogenesis models
• Closed-loop control of tumor growth by means of anti-angiogenic administration
• A bi-parametric model for the tumour angiogenesis and antiangiogenesis therapy
• Tumor development under combination treatments with anti-angiogenic therapies
• Mathematical model of cancer growth controled by metronomic chemotherapies
• Combined therapy for treating solid tumors with chemotherapy and angiogenic inhibitors
• Title not available (Why is that?)
• Modelling pulsed immunotherapy of tumour-immune interaction
• Optimal control of cancer treatments: mathematical models for the tumor microenvironment
• Optimal control for a bone metastasis with radiotherapy model using a linear objective functional
• Chemotherapy of vascularised tumours: role of vessel density and the effect of vascular ``pruning
• Optimal and suboptimal protocols for a class of mathematical models of tumor anti-angiogenesis
• What mathematical models can or cannot do in glioma description and understanding
• On the role of pharmacometrics and the objective in optimizing cancer therapies
• Optimal control problems for differential equations applied to tumor growth: state of the art
• Stability analysis of the family of tumour angiogenesis models with distributed time delays

This page was built for publication: Optimal scheduling of radiotherapy and angiogenic inhibitors

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q253387)